报价延迟最少15分钟:2026/10/25 17:23 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.92 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.35/-0.57
|
|
企业价值
525.24M
|
| 资产负债 |
|
每股账面净值
0.04
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
42.00K
|
|
每股收益
0.00
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel. |
